HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kristian Strømgaard Selected Research

Kristian Strømgaard Research Topics

Disease

8Stroke (Strokes)
01/2021 - 02/2012
5Pain (Aches)
01/2020 - 10/2010
4Neuralgia (Stump Neuralgia)
01/2020 - 01/2010
4Neurodegenerative Diseases (Neurodegenerative Disease)
10/2019 - 04/2006
4Brain Diseases (Brain Disorder)
01/2015 - 10/2008
3Neoplasms (Cancer)
01/2022 - 01/2020
3Herpes Zoster
11/2021 - 07/2019
3Ischemic Stroke
01/2021 - 01/2015
3Infections
01/2021 - 10/2018
3Brain Ischemia (Cerebral Ischemia)
01/2019 - 10/2010
3Mental Disorders (Mental Disorder)
10/2016 - 04/2014
2Metabolic Diseases (Metabolic Disease)
07/2019 - 11/2013
2Infarction (Infarctions)
01/2019 - 02/2012
2Alzheimer Disease (Alzheimer's Disease)
03/2018 - 03/2011
2Traumatic Brain Injuries (Traumatic Brain Injury)
12/2017 - 10/2017
2Hypersensitivity (Allergy)
06/2016 - 04/2013
2Obesity
11/2013 - 09/2013
2Cocaine-Related Disorders (Cocaine Addiction)
10/2010 - 01/2010
1Glioblastoma (Glioblastoma Multiforme)
11/2021
1Acquired Immunodeficiency Syndrome (AIDS)
01/2021
1Pathologic Processes
01/2020
1Virus Diseases (Viral Diseases)
07/2019
1Ischemia
01/2019
1Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
01/2019
1Brain Injuries (Brain Injury)
10/2017
1Hypocalcemia
01/2017
1Hyperphosphatemia
01/2017
1Chronic Pain
04/2013
1Major Depressive Disorder (Major Depressive Disorders)
07/2011
1Carcinogenesis
02/2011
1Nervous System Diseases (Neurological Disorders)
09/2004

Drug/Important Bio-Agent (IBA)

11Proteins (Proteins, Gene)FDA Link
11/2021 - 10/2008
6N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA
01/2021 - 10/2008
6Pharmaceutical PreparationsIBA
01/2020 - 10/2010
4Peptides (Polypeptides)IBA
11/2021 - 11/2013
3Amyloid (Amyloid Fibrils)IBA
10/2019 - 03/2018
3AMPA Receptors (AMPA Receptor)IBA
01/2010 - 09/2004
2Disks Large Homolog 4 ProteinIBA
11/2021 - 11/2021
2N-Methylaspartate (NMDA)IBA
01/2021 - 01/2019
2Glutamate Receptors (Glutamate Receptor)IBA
01/2020 - 04/2006
2UCCB01-144IBA
01/2019 - 06/2016
2Ionotropic Glutamate ReceptorsIBA
01/2018 - 09/2004
2Therapeutic UsesIBA
12/2017 - 10/2017
2Neuroprotective AgentsIBA
05/2017 - 02/2012
2Dopamine (Intropin)FDA LinkGeneric
10/2016 - 10/2015
2Serotonin (5 Hydroxytryptamine)IBA
10/2016 - 04/2014
2Neurotransmitter Agents (Neurotransmitter)IBA
10/2016 - 04/2014
2UCCB01-125IBA
06/2016 - 04/2013
2Freund's AdjuvantIBA
06/2016 - 04/2013
2Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA
04/2014 - 07/2011
11H-tetrazole (tetrazole)IBA
01/2022
1LigandsIBA
11/2021
1SynteninsIBA
11/2021
1Nitric Oxide Synthase Type I (Neuronal Nitric Oxide Synthase)IBA
01/2021
1Heparin (Liquaemin)FDA LinkGeneric
01/2021
1postsynaptic density proteinsIBA
01/2021
1GTP-Binding Proteins (G-Protein)IBA
01/2020
1CationsIBA
01/2020
1Protons (Proton)IBA
01/2020
1alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)IBA
01/2020
1Heterotrimeric GTP-Binding Proteins (Heterotrimeric G-Proteins)IBA
01/2020
1Acid Sensing Ion ChannelsIBA
01/2020
1Biological ProductsIBA
10/2019
1PolyphenolsIBA
10/2019
1Glucagon (Glukagon)FDA Link
07/2019
1Glucagon-Like Peptide 1 (GLP 1)IBA
07/2019
1Glucagon-Like Peptides (Enteroglucagon)IBA
07/2019
1Tat-NR2B9cIBA
01/2019
1Anti-Bacterial Agents (Antibiotics)IBA
10/2018
1Presenilin-1IBA
03/2018
1Parathyroid Hormone (Parathormone)IBA
01/2017
1Analgesics (Analgesic Drugs)IBA
06/2016
1Illicit Drugs (Recreational Drugs)IBA
10/2015
1Norepinephrine (Noradrenaline)FDA LinkGeneric
10/2015
1Ion Channels (Ion Channel)IBA
01/2015
1Nitric Oxide (Nitrogen Monoxide)FDA Link
04/2013
1Dizocilpine Maleate (Dizocilpine)IBA
04/2013
1Tat-NPEG4(IETDV)2IBA
02/2012
1Norepinephrine Plasma Membrane Transport Proteins (Norepinephrine Transporter)IBA
07/2011
1Phosphotransferases (Kinase)IBA
10/2010
1FSC 231IBA
01/2010
1propionic acid (potassium propionate)IBA
09/2004

Therapy/Procedure

5Therapeutics
11/2021 - 01/2010
1Drug Therapy (Chemotherapy)
07/2019
1Anesthesia
01/2017
1Aftercare (After-Treatment)
04/2013
1Intravenous Injections
02/2012